The researchers found that major ischemic events occurred in 5.0 and 6.5% of patients receiving clopidogrel plus aspirin vs aspirin plus placebo, respectively (hazard ratio, 0.75); most events occurred during the first week after the initial event.
The researchers found that 53.3 and 41.8% of the alteplase and placebo groups, respectively, had a favorable outcome at 90 days (adjusted odds ratio, 1.61).
At the end of 6 months, the rate of VTE recurrence was 4% among rivaroxaban patients vs 11% in the dalteparin arm (hazard ratio [HR] 0.43, 95% CI: 0.19 to 0.99).
The 1-year cardiovascular mortality hazard ratio (HR) for alendronate users was 0.33 (95% CI, 0.17 to 0.65) and 0.55 for incident myocardial infarction (95% CI, 0.34 to 0.89).
The researchers found that there were increased cardiovascular risks among endometrial cancer survivors for phlebitis, thrombophlebitis, and thromboembolism (hazard ratio, 2.07); pulmonary heart disease (hazard ratio, 1.74); and atrial fibrillation (hazard ratio, 1.5).
Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA's Accelerated Approval pathway.
When treated with tenecteplase, stroke patients eligible for mechanical thrombectomy had higher rates of reperfusion and superior clinical outcomes at 90 days relative to patients treated with alteplase.
In this meta-analysis of prospective population-based studies, sickle cell trait (SCT) was not associated with any difference in risk of first ischemic stroke.
Most cases were insured by federal and/or state programs (73.6 and 10.1%, respectively), but many (44.9%) patients were considered under-insured. In 2015, hospital charges of $4,580,786.88 were identified for the 66 cases of illicit drug-associated endocarditis.
The researchers found that the primary outcome occurred in 22 and 10% of those treated with tenecteplase and alteplase, respectively
Findings suggested that the rate of in-hospital mortality after pediatric stroke was 1.5% for neonates and 3.1% in children/adolescents. The authors also found that the strongest risk factors for mortality were congenital heart disease and stroke that involved both anterior and posterior circulation.
Results showed that compared to metoprolol, those who initiated carvedilol had a greater all-cause (HR, 1.08; 95% CI,1.02-1.16) and cardiovascular mortality (HR, 1.18; 95% CI, 1.08-1.29).
"These data support limits for alcohol consumption that are lower than those recommended in most current guidelines," the authors write.
The researchers identified significant inverse associations between coffee consumption (more than 3 cups/day) and CAC ≥100 (odds ratio, 0.33 for more than three cups/day).
"Although outcomes-based pricing may have a role in other settings, our analysis of its application to PCSK9 inhibitors - effective preventive medications with a high price tag - shows the potential limitation of this approach for high-cost preventive therapies," the authors write.
The researchers found that oral anticoagulation therapy was initiated within 30 days post-discharge in 8.4 and 42.9% of those with POAF and NVAF, respectively.
Patients with higher modified Rankin Scale (mRS) levels had worse scores, though the association between scores and mRS level varied. Physical function, satisfaction with social roles, and executive function were the most affected domains.
Using Medicaid claims from 5 states (1999-2010) and Medicare claims for dual-enrollees, study authors analyzed the first concomitant use of clopidogrel and 1 of 10 selected NSAIDs (ibuprofen, celecoxib, naproxen, rofecoxib, meloxicam, diclofenac, indomethacin, valdecoxib, nabumetone, etodolac) after a 1-year baseline period.
The primary efficacy outcome was the combined rate of death from a cardiovascular cause, heart attack, stroke due to inadequate blood supply, blood clots or amputation due to cardiovascular disease.
The ODYSSEY Outcomes trial (N=18,924) evaluated the effect of alirocumab on the occurrence of MACE in patients who had an ACS between 1-12 months prior to trial enrollment, and who were already taking maximally-tolerated statins (atorvastatin or rosuvastatin).
After 30 days of treatment the analysis found that major bleeding - the most common complication with blood thinners - occurred at the same level (0.7%) for patients in both treatment groups
Aspirin comparable to rivaroxaban for extended venous thromboembolism prophylaxis following arthroplasty
Patients initially treated with rivaroxaban following total knee or hip arthroplasty experienced similar rates of venous thromboembolism (VTE) regardless of continued rivaroxaban use or switching to aspirin for extended VTE prophylaxis.
Patients presenting with ischemic stroke 6 to 16 hours after they were last known to be well had improved functional outcomes at 90 days if treated with thrombectomy and medical therapy compared to medical therapy alone.
The Agency is asking healthcare professionals to use caution before prescribing the antibiotic to this patient population.
Results showed the crude hazard ratio (HR) of major cardiovascular events was 1.99 (95% CI, 1.28-3.09) for COX-2 vs. nonselective NSAIDs.